Inhaled insulin getting close look by FDA

09/8/2005 | Reuters

The FDA has asked an advisory panel to consider if an inhaled insulin powder developed by Pfizer, Sanofi-Aventis and Nektar Therapuetics could have adverse effects on the lungs or blood sugar levels. The panel is scheduled to review Exubera today, and some analysts project the product, if approved, could generate sales of up to $2 billion a year.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA